bevacizumab,trifluridine tipiracil
taiho pharma,roche,otsuka
[]
data from the phase 3 sunlight study point to trifluridine/tipiracil plus bevacizumab as practice-changing care for 3rd line treatment of refractory metastatic colorectal cancer #gi23 